Literature DB >> 12426560

T cells require TRAIL for optimal graft-versus-tumor activity.

Cornelius Schmaltz1, Onder Alpdogan, Barry J Kappel, Stephanie J Muriglan, Jimmy A Rotolo, Jennifer Ongchin, Lucy M Willis, Andrew S Greenberg, Jeffrey M Eng, James M Crawford, George F Murphy, Hideo Yagita, Henning Walczak, Jacques J Peschon, Marcel R M van den Brink.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that exhibits specific tumoricidal activity against a variety of tumors. It is expressed on different cells of the immune system and plays a role in natural killer cell-mediated tumor surveillance. In allogeneic hematopoietic-cell transplantation, the reactivity of the donor T cell against malignant cells is essential for the graft-versus-tumor (GVT) effect. Cytolytic activity of T cells is primarily mediated through the Fas-Fas ligand and perforin-granzyme pathways. However, T cells deficient for both Fas ligand and perforin can still exert GVT activity in vivo in mouse models. To uncover a potential role for TRAIL in donor T cell-mediated GVT activity, we compared donor T cells from TRAIL-deficient and wild-type mice in clinically relevant mouse bone-marrow transplantation models. We found that alloreactive T cells can express TRAIL, but the absence of TRAIL had no effect on their proliferative and cytokine response to alloantigens. TRAIL-deficient T cells showed significantly lower GVT activity than did TRAIL-expressing T cells, but no important differences in graft-versus-host disease, a major complication of allogeneic hematopoietic cell transplantation, were observed. These data suggest that strategies to enhance TRAIL-mediated GVT activity could decrease relapse rates of malignancies after hematopoietic cell transplantation without exacerbation of graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426560     DOI: 10.1038/nm1202-797

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  38 in total

Review 1.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

2.  Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.

Authors:  Barry J Kappel; Javier Pinilla-Ibarz; Adam A Kochman; Jeffrey M Eng; Vanessa M Hubbard; Ingrid Leiner; Eric G Pamer; Glen Heller; Marcel R M van den Brink; David A Scheinberg
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

3.  Blazing a new TRAIL in hematopoietic cell transplantation.

Authors:  Nelson Chao
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

4.  Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Authors:  Arnab Ghosh; Melody Smith; Scott E James; Marco L Davila; Enrico Velardi; Kimon V Argyropoulos; Gertrude Gunset; Fabiana Perna; Fabiana M Kreines; Emily R Levy; Sophie Lieberman; Hillary V Jay; Andrea Z Tuckett; Johannes L Zakrzewski; Lisa Tan; Lauren F Young; Kate Takvorian; Jarrod A Dudakov; Robert R Jenq; Alan M Hanash; Ana Carolina F Motta; George F Murphy; Chen Liu; Andrea Schietinger; Michel Sadelain; Marcel R M van den Brink
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

Review 5.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

Review 7.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

9.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

10.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.